Environmental, Health & Safety (EHS) considerations are an integrated part of our every day work. Our main concerns include reducing our consumption of resources, such as water, energy and chemicals, and reducing atmospheric emissions from the production process, and also preventing any contact with chemicals.
Our dedicated EHS department encourages the environmental, health and safety consciousness of our staff, by ensuring that each member has the necessary skills and knowledge to minimise environmental impact and secure a healthy and safe environment while on the job.
In 2019 we adapted Novo Nordisk bold environmental strategy, Circular for Zero. Our ambition is Zero environmental impact by 2030. An ambition we came one step closer to in 2018, were we became CO2 neutral with renewable energy produced by windmills.
We are DS/EN ISO 14001 as well as DS/EN ISO 45001 certified.
The most significant impacts on the environment of our activities are: emission of CO2, atmospheric emission of organic solvents used in manufacturing processes, disposal of hazardous waste – mainly chemical residues from production and laboratories. In addition, we have a number of outdoor facilities such as ventilation systems, cooling systems and pumps, all of which brings us close to our granted noise limits during evenings and nights. Finally, there is the risk of major accidents related to the handling and storage of hazardous chemicals.
We fully realize that the operation of a chemical company may affect the environment. Environmental considerations are therefore integrated in our daily operations, and we find it important to reduce our environmental impact to a minimum.
We must all act responsibly to attain sustainable development. Novo Nordisk Pharmatech A/S is a company in constant development. We work at developing new products and processes. While doing so, we are dedicated to taking part in reducing the environmental impacts.
Open, trustworthy and timely stakeholder communication is a prerequisite for our work. This applies to external communication with neighbours, authorities, customers and suppliers, as well as to internal communication with our employees.
It is our ambition at Novo Nordisk Pharmatech A/S to be at all times a safe, attractive and modern workplace, which proactively and continuously is improving its working environment.
We are a specialized chemical company, manufacturing products with high documentation requirements. We develop and manufacture quaternary ammonium compounds mainly for use in the medicinal and veterinary sectors, as well as for cosmetics and disinfection. Other products such as substituted silica gels are also prepared, for use in the manufacturing process of Novo Nordisk A/S’ strategic products.
For a majority of employees, the main occupational safety concern is the handling of chemicals in connection with production, analysis and development. Working at Novo Nordisk Pharmatech also includes operation and maintenance activities, where the most significant safety concern is the risk for body injuries. Other employees have administrative occupations, where they ensure that the company lives up to the continuously increasing standards within quality, environment, working environment, safety and energy. Their main occupational safety concerns are typical for office workers.
We will create a safe work place by using the best technologies. We will respect regulations and other requirements that we adhere to, and ensure that occupational safety is being handled by our management systems. Through company management, all employees will take responsibility for themselves and others through a positive involvement in safety tasks, because safety is an important part of our culture.
Novo Nordisk Pharmatech has worked intensively to improve and maintain a sustainable approach to the well-being of our employees.
In the past few years, Novo Nordisk Pharmatech has performed yearly training of managers and employees in preventing stress and maintaining well-being, implemented dialogue-based assessment of stress symptoms and continuous follow up. This has resulted in a significant decrease in stress-related absence and a level close to zero by the end of the year.
In terms of absence due to illness, we have in 2020 continued the intensive work we initiated in 2019, where employees with complex long-term illnesses were supported with back-to-work plans and/or best possible alternative solutions in close collaboration with local municipalities, medical doctors and Novo Nordisk social counselors. The result has been a continuous positive trend throughout 2020 and a reduction of absence by 20% compared to 2019. By the end of the year absence due to illness was 3.1%
We have changed our performance-management approach to focus on behaviour through continuous dialogue and feedback between manager and employee. Behavioural targets are designed from the Novo Nordisk Way and our Novo Nordisk Pharmatech United Culture, which has particular emphasis on strengthening our commercial mindset, our focus on simplicity and our ability to collaborate across departments
As a Novo Nordisk company, we work with the “Triple Bottom Line” principle, the CO2 Reduction program, and follow Novo Nordisk’s People Policy.
We strive to conduct our activities in a financially, environmentally and socially responsible way. This implies that any decision should always seek to balance three considerations:
This principle ensures that decision-making balances financial growth with corporate responsibility, short-term gains with long-term profitability and shareholder return with other stakeholder interests.
In 2019, Novo Nordisk Pharmatech committed to Novo Nordisk’s Circular for Zero environmental strategy, meaning the company strives toward having zero environmental impact by 2030. In 2019 Novo Nordisk Pharmatech implemented Circular for Zero by carrying out awareness and idea-generating workshops with every department within the company and established local Circular for Zero 2025 targets.
In 2020, Novo Nordisk Pharmatech has mapped our suppliers’ CO2 emissions. By 2030, Novo Nordisk Pharmatech will require that all of our supply must be based on 100% renewable power. Furthermore in 2020, Novo Nordisk Pharmatech has established 10 electrical car-charging stations, started the process for a paperless office, and have planned to substitute some of the most hazardous chemicals in our production for more environmentally friendly alternatives.
Your message has been sent!
An error has occured
Please send us an email at email@example.com